Patent US4623662A successfully refreshed from Google Patents.
US4623662A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Antiatherosclerotic ureas and thioureas
Assignee: Wyeth Holdings LLC
•
Filing: 1985-05-23
•
Granted: 1986-11-18
•
Expires: 2005-05-23
Abstract
Abstract This invention is concerned with ureas and thioureas which may be represented by the formula: ##STR1## wherein X represents at least one substituent selected from the group consisting of (C 1 -C 4 )alkyl, (C 1 -C 4 )alkenyl, (C 1 -C 4 )alkynyl, phenoxy, mercapto, amino, (C 1 -C 4 )alkylamino, di-(C 1 -C 4 )alkylamino, halo, trihalomethyl, (C 1 -C 4 )alkanoyl), benzoyl, (C 1 -C 4 )alkanamido, haloacetamido, nitro, cyano, carboxy, (C 1 -C 4 )carboalkoxy, carbamoyl, sulfamyl, methylenedioxy, phenyl, orthophenylene, tolyl, benzyl, halobenzyl, methylbenzyl; Y is selected from the group consisting of oxygen and sulfur; R 1 and R 2 are different and are independently selected from the group consisting of (C 4 -C 12 )alkyl, (C 4 -C 12 )alkenyl, (C 4 -C 12 )alkynyl, (C 4 -C 12 )cycloalkylalkyl, (C 7 -C 14 )aralkyl, and (C 7 -C 14 )aralkyl in which an aromatic ring bears at least one substituent selected from the group consisting of (C 1 -C 10 )alkyl, (C 1 -C 10 )alkoxy, phenoxy, benzyloxy, methylenedioxy, (C 1 -C 14 )alkylthio, phenyl, halo, trihalomethyl, adamantyl, (C 1 -C 4 )carboalkoxy, and nitro.
Inventors
- 👤 Vern G. De Vries
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 18:24
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/16; A61K31/17
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
219 words
A method of reducing the cholesterol ester content of an arterial wall, inhibiting atherosclerotic lesion development, and/or treating hyperlipidemia in a mammal in need of such treatment which comprises administering to said mammal an effective amount of a compound of the formula: ##STR8## wherein X represents at least one substituent selected from the group consisting of (C 1 -C 4 )alkyl, (C 1 -C 4 )alkenyl, (C 1 -C 4 )alkynyl, phenoxy, mercapto, amino, (C 1 -C 4 )alkylamino, di(C 1 -C 4 )alkylamino, halo, trihalomethyl, (C 1 -C 4 )alkanoyl, benzoyl, (C 1 -C 4 )alkanamido, haloacetamido, nitro, cyano, carboxy, (C 1 -C 4 )carboalkoxy, carbamoyl, sulfamyl, methylenedioxy, phenyl, ortho-phenylene, tolyl, benzyl, halobenzyl, methylbenzyl; Y is selected from the group consisting of oxygen and sulfur; R 1 and R 2 are different and are independently selected from the group consisting of (C 4 -C 12 )alkyl, (C 4 -C 12 )alkenyl, (C 4 -C 12 )alkynyl, C 4 -C 12 ) cycloalkylalkyl, (C 7 -C 14 )aralkyl, and (C 7 -C 14 )aralkyl in which an aromatic ring bears at least one substituent selected from the group consisting of (C 1 -C 10 )alkyl, (C 1 -C 10 )alkoxy, phenoxy, benzyloxy, methylenedioxy, (C 1 -C 4 )alkylthio, phenyl, halo, trihalomethyl, adamantyl, (C 1 -C 4 )carboalkoxy and nitro.
Claim 2
Independent Claim
219 words
A method of reducing the cholesterol ester content of an arterial wall, inhibiting atherosclerotic lesion development, and/or treating hyperlipidemia in a mammal in need of such treatment which comprises administering to said mammal an effective amount of a compound of the formula: ##STR8## wherein X represents at least one substituent selected from the group consisting of (C 1 -C 4 )alkyl, (C 1 -C 4 )alkenyl, (C 1 -C 4 )alkynyl, phenoxy, mercapto, amino, (C 1 -C 4 )alkylamino, di(C 1 -C 4 )alkylamino, halo, trihalomethyl, (C 1 -C 4 )alkanoyl, benzoyl, (C 1 -C 4 )alkanamido, haloacetamido, nitro, cyano, carboxy, (C 1 -C 4 )carboalkoxy, carbamoyl, sulfamyl, methylenedioxy, phenyl, ortho-phenylene, tolyl, benzyl, halobenzyl, methylbenzyl; Y is selected from the group consisting of oxygen and sulfur; R 1 and R 2 are different and are independently selected from the group consisting of (C 4 -C 12 )alkyl, (C 4 -C 12 )alkenyl, (C 4 -C 12 )alkynyl, C 4 -C 12 ) cycloalkylalkyl, (C 7 -C 14 )aralkyl, and (C 7 -C 14 )aralkyl in which an aromatic ring bears at least one substituent selected from the group consisting of (C 1 -C 10 )alkyl, (C 1 -C 10 )alkoxy, phenoxy, benzyloxy, methylenedioxy, (C 1 -C 4 )alkylthio, phenyl, halo, trihalomethyl, adamantyl, (C 1 -C 4 )carboalkoxy and nitro.
Claim 3
Dependent Claim
11 words
A method as recited in claim 1 wherein Y is oxygen.
Claim 4
Dependent Claim
19 words
A method as recited in claim 2 wherein X represents at least two (C 1 -C 4 )alkyl substituents.
Claim 5
Dependent Claim
15 words
A method as recited in claim 2 wherein X represents at least one halo substituent.
Claim 6
Dependent Claim
33 words
A method as recited in claim 2 wherein R 1 is (C 7 -C 14 )aralkyl bearing a (C 1 -C 10 )alkyl substituent and R 2 is (C 4 -C 12 )alkyl.
Claim 7
Dependent Claim
21 words
A method as recited in claim 2 wherein R 1 is 4-(2,2-dimethylpropyl)phenylmethyl and R 2 is (C 4 -C 12 )alkyl.
Claim 8
Dependent Claim
27 words
A method as recited in claim 2 wherein X represents at least one substituent selected from the group consisting of (C 1 -C 4 )alkyl and halo.
Claim 9
Dependent Claim
12 words
A method as recited in claim 2 wherein the compound is 1-(n-heptyl)-1-[4(n-butyl)benzyl]-3-(2-,4-difluorophenyl)urea.
Claim 10
Dependent Claim
12 words
A method as recited in claim 2 wherein the compound is 1-(3,3-dimethylbutyl-1-[4-(4-(n-butyl)benzyl]-3-(4-chloro-2,6-dimethylphenyl)urea.
Claim 11
Dependent Claim
12 words
The method as recited in claim 2 wherein the compound is 1-(3,3-dimethylbutyl)-1-[4-(2,2-dimethylpropyl)-benzyl]-3-(4-chloro-2,6-dimethylphenyl)urea.
Claim 12
Dependent Claim
12 words
A method as recited in claim 2 wherein the compound is 1-(n-heptyl)-1-[4-(2,2-dimethylpropyl)phenylmethyl]-3-(2,4-difluorophenyl)urea.
References Cited (Backward Citations)
US2709648A
Cited
US2867520A
Cited
US2993930A
Cited
US3326663A
Cited
US3897493A
Cited
US4010281A
Cited
US4127673A
Cited
US4405644A
Cited
US4387105A
Cited
US4387106A
Cited
US4397868A
Cited
US4473579A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-11-17 | 1990-05-19 | 1990-11-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-11-17 | 1994-05-19 | 1994-11-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-11-17 | 1998-05-19 | 1998-11-18 | $7700.00 | Window Closed / Lapsed |